Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus EXSERVAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus EXSERVAN.
BREO ELLIPTA vs EXSERVAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Exservan (riluzole) is a benzothiazole derivative that modulates glutamatergic neurotransmission. Its mechanism of action involves inhibition of glutamate release, inactivation of voltage-dependent sodium channels, and interference with neurotransmitter binding to excitatory amino acid receptors.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
Adults: 15 mg orally once daily in the morning; increase to 30 mg after 2 weeks if needed. Maximum 30 mg/day.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal elimination half-life is approximately 3–4 hours in patients with normal renal function; prolonged in renal impairment (up to 8–10 hours in ESRD).
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Primarily renal excretion as unchanged drug: 80% excreted unchanged in urine; approximately 20% as metabolites; biliary/fecal <5%.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid